Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Tanespimycin: Additional Phase Ib data

KOSN said that 340 mg/m 2 of its tanespimycin produced lower response rates than those seen in an earlier group given

Read the full 210 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE